JP2010514681A - 抗凝血剤として有用な大環状第ｖｉｉａ因子阻害剤 - Google Patents
抗凝血剤として有用な大環状第ｖｉｉａ因子阻害剤 Download PDFInfo
- Publication number
- JP2010514681A JP2010514681A JP2009543158A JP2009543158A JP2010514681A JP 2010514681 A JP2010514681 A JP 2010514681A JP 2009543158 A JP2009543158 A JP 2009543158A JP 2009543158 A JP2009543158 A JP 2009543158A JP 2010514681 A JP2010514681 A JP 2010514681A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- phenyl
- ring
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CCCC*(CCCCN)** Chemical compound CCCC*(CCCCN)** 0.000 description 38
- HEZFEXJWASFHPH-UHFFFAOYSA-N C#[N]N(Cc1ccccc11)S1(=O)=O Chemical compound C#[N]N(Cc1ccccc11)S1(=O)=O HEZFEXJWASFHPH-UHFFFAOYSA-N 0.000 description 1
- PIDDQVOJMCUFPQ-WYDVEAGSSA-N C/C=C(/C)\[C@H](CCN)C(C)=O Chemical compound C/C=C(/C)\[C@H](CCN)C(C)=O PIDDQVOJMCUFPQ-WYDVEAGSSA-N 0.000 description 1
- GIRDSMWNWLWKDG-UHFFFAOYSA-N C=CPS(c(c(C#N)c1)ccc1[N+]([O-])=O)(=O)=O Chemical compound C=CPS(c(c(C#N)c1)ccc1[N+]([O-])=O)(=O)=O GIRDSMWNWLWKDG-UHFFFAOYSA-N 0.000 description 1
- PXYBYYNMCOMEEG-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cc(cc1)N)c1S(C1CC1)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)Cc(cc(cc1)N)c1S(C1CC1)(=O)=O)=O PXYBYYNMCOMEEG-UHFFFAOYSA-N 0.000 description 1
- VFOOMWZVNYSLAL-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cc(cc1)NC(CCCc2c(C)cc(C(C(O)=O)Nc3ccc(CNC4=O)c4c3)cc2C)=O)c1S(C1CC1)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)Cc(cc(cc1)NC(CCCc2c(C)cc(C(C(O)=O)Nc3ccc(CNC4=O)c4c3)cc2C)=O)c1S(C1CC1)(=O)=O)=O VFOOMWZVNYSLAL-UHFFFAOYSA-N 0.000 description 1
- NQUGFSFCUKXIMY-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cc(cc1)[N+]([O-])=O)c1N(CCC1)C1=O)=O Chemical compound CC(C)(C)OC(N(C)Cc(cc(cc1)[N+]([O-])=O)c1N(CCC1)C1=O)=O NQUGFSFCUKXIMY-UHFFFAOYSA-N 0.000 description 1
- GOBPZSXUTYYGHA-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc1c(CO)ccc([N+]([O-])=O)c1)=O Chemical compound CC(C)(C)OC(N(C)Cc1c(CO)ccc([N+]([O-])=O)c1)=O GOBPZSXUTYYGHA-UHFFFAOYSA-N 0.000 description 1
- KRKYHIIJYJMCID-TZYYSAMKSA-N CC(C)(C)OC(N(C)Cc1cc(NC(OC[C@@H](c2ccc(C(C(O)=O)Nc3ccc(C=CNC4=O)c4c3)cc2)OC)=O)ccc1S(C1CC1)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)Cc1cc(NC(OC[C@@H](c2ccc(C(C(O)=O)Nc3ccc(C=CNC4=O)c4c3)cc2)OC)=O)ccc1S(C1CC1)(=O)=O)=O KRKYHIIJYJMCID-TZYYSAMKSA-N 0.000 description 1
- BGGAVURNIPQGMV-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc1cc([N+]([O-])=O)ccc1N(CCC1)S1(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)Cc1cc([N+]([O-])=O)ccc1N(CCC1)S1(=O)=O)=O BGGAVURNIPQGMV-UHFFFAOYSA-N 0.000 description 1
- UAPSLZLJFXZLPC-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc1cc([N+]([O-])=O)ccc1Oc1ccccc1)=O Chemical compound CC(C)(C)OC(N(C)Cc1cc([N+]([O-])=O)ccc1Oc1ccccc1)=O UAPSLZLJFXZLPC-UHFFFAOYSA-N 0.000 description 1
- KWNAFILBLSJYIU-UHFFFAOYSA-N CC(COC(Nc(cc1CNC)ccc1S(C1CC1)(=O)=O)=O)c1c(C)cc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1 Chemical compound CC(COC(Nc(cc1CNC)ccc1S(C1CC1)(=O)=O)=O)c1c(C)cc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1 KWNAFILBLSJYIU-UHFFFAOYSA-N 0.000 description 1
- ZUPXFEJXZHBTAO-UHFFFAOYSA-N CCCS(c(c(CN(C)C(OC(C)(C)C)=O)c1)ccc1NC(OCCc1c(C)cc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1C)=O)(=O)=O Chemical compound CCCS(c(c(CN(C)C(OC(C)(C)C)=O)c1)ccc1NC(OCCc1c(C)cc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1C)=O)(=O)=O ZUPXFEJXZHBTAO-UHFFFAOYSA-N 0.000 description 1
- YWJALFKBIPTNMY-UHFFFAOYSA-N CCCS(c(c(CN(C)C(OC(C)(C)C)=O)c1)ccc1NC(OCCc1ccc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1)=O)(=O)=O Chemical compound CCCS(c(c(CN(C)C(OC(C)(C)C)=O)c1)ccc1NC(OCCc1ccc(C(C(O)=O)Nc(cc2)cc3c2N=CNC3=O)cc1)=O)(=O)=O YWJALFKBIPTNMY-UHFFFAOYSA-N 0.000 description 1
- ZRSIXVKNXWUFHR-CQHAJPFMSA-N CCN(Cc1cc(N)ccc1)C(C(c1cc(C)c([C@@H](C)CO)cc1)Nc(cc1)cc2c1C=CNC2=O)=O Chemical compound CCN(Cc1cc(N)ccc1)C(C(c1cc(C)c([C@@H](C)CO)cc1)Nc(cc1)cc2c1C=CNC2=O)=O ZRSIXVKNXWUFHR-CQHAJPFMSA-N 0.000 description 1
- PWSYYQYGWHGIGO-MTDXEUNCSA-N CCOC(/C=C(\c1cc(N)ccc1)/NC(C(c1cc(C)c(CCO)c(C)c1)Nc1ccc(C=CNC2=O)c2c1)=O)=O Chemical compound CCOC(/C=C(\c1cc(N)ccc1)/NC(C(c1cc(C)c(CCO)c(C)c1)Nc1ccc(C=CNC2=O)c2c1)=O)=O PWSYYQYGWHGIGO-MTDXEUNCSA-N 0.000 description 1
- FOCWSWROSLSESQ-UHFFFAOYSA-N CCOC(CCNCc1cccc([N+]([O-])=O)c1)=O Chemical compound CCOC(CCNCc1cccc([N+]([O-])=O)c1)=O FOCWSWROSLSESQ-UHFFFAOYSA-N 0.000 description 1
- WBDHXENIXNCVBE-UHFFFAOYSA-N CCS(C1CC1)c(cc1)c(CN(C)C(C(c2ccc(C3(CC3)CO3)cc2)Nc2ccc(C=CNC4=O)c4c2)=O)cc1NC3=O Chemical compound CCS(C1CC1)c(cc1)c(CN(C)C(C(c2ccc(C3(CC3)CO3)cc2)Nc2ccc(C=CNC4=O)c4c2)=O)cc1NC3=O WBDHXENIXNCVBE-UHFFFAOYSA-N 0.000 description 1
- MUVFYJAPWFFXIB-ZAFBDEJNSA-N CCc1c([C@@H](C)COC(Nc2cccc(CN(C)C(C3Nc4ccc(C=CNC5=O)c5c4)=O)c2)=O)ccc3c1 Chemical compound CCc1c([C@@H](C)COC(Nc2cccc(CN(C)C(C3Nc4ccc(C=CNC5=O)c5c4)=O)c2)=O)ccc3c1 MUVFYJAPWFFXIB-ZAFBDEJNSA-N 0.000 description 1
- RWTCSHHZECQGOW-SJLPKXTDSA-N CCc1c([C@H](C(N([C@H](Cc2ccccc2)CO2)C2=O)=O)N)ccc(Br)c1 Chemical compound CCc1c([C@H](C(N([C@H](Cc2ccccc2)CO2)C2=O)=O)N)ccc(Br)c1 RWTCSHHZECQGOW-SJLPKXTDSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CUPACEJGEFNQCI-FQEVSTJZSA-N CNCc1cc(NC(OC[C@@H](c(cc2)ccc2Br)OCOC)=O)ccc1S(C1CC1)(=O)=O Chemical compound CNCc1cc(NC(OC[C@@H](c(cc2)ccc2Br)OCOC)=O)ccc1S(C1CC1)(=O)=O CUPACEJGEFNQCI-FQEVSTJZSA-N 0.000 description 1
- KDWIPRSJJDPGHY-UHFFFAOYSA-N CNCc1cc([N+]([O-])=O)ccc1-[n]1nccc1 Chemical compound CNCc1cc([N+]([O-])=O)ccc1-[n]1nccc1 KDWIPRSJJDPGHY-UHFFFAOYSA-N 0.000 description 1
- XEQXZXOTHYBOAC-JTQLQIEISA-N COCO[C@@H](CO)c(cc1)ccc1Br Chemical compound COCO[C@@H](CO)c(cc1)ccc1Br XEQXZXOTHYBOAC-JTQLQIEISA-N 0.000 description 1
- NUSLHCMXGXTSIB-VIFPVBQESA-N CO[C@@H](CO)c(cc1)ccc1Br Chemical compound CO[C@@H](CO)c(cc1)ccc1Br NUSLHCMXGXTSIB-VIFPVBQESA-N 0.000 description 1
- CPEDKQHROTYYCB-UHFFFAOYSA-N COc1cc(Br)cc(OC)c1C=C Chemical compound COc1cc(Br)cc(OC)c1C=C CPEDKQHROTYYCB-UHFFFAOYSA-N 0.000 description 1
- UJGUWWZOHPAMAJ-UHFFFAOYSA-N COc1cc(Br)cc(OC)c1N Chemical compound COc1cc(Br)cc(OC)c1N UJGUWWZOHPAMAJ-UHFFFAOYSA-N 0.000 description 1
- IORLMMQRQVGMDV-QMMMGPOBSA-N COc1cc(Br)ccc1[C@H](CO)N Chemical compound COc1cc(Br)ccc1[C@H](CO)N IORLMMQRQVGMDV-QMMMGPOBSA-N 0.000 description 1
- HBKDBYVWUOKPLQ-NRFANRHFSA-N C[C@@H](CCC(Nc(cc1)cc(CN(C)C(CNc(cc2)cc3c2C=CNC3=O)=O)c1OC(F)(F)F)=O)c1ccc(C)cc1OC Chemical compound C[C@@H](CCC(Nc(cc1)cc(CN(C)C(CNc(cc2)cc3c2C=CNC3=O)=O)c1OC(F)(F)F)=O)c1ccc(C)cc1OC HBKDBYVWUOKPLQ-NRFANRHFSA-N 0.000 description 1
- NCLDDWDALDODOQ-ADXZGYQBSA-N C[C@@H](CCC(Nc1cc(CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)ccc1)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](CCC(Nc1cc(CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)ccc1)=O)c1c(C)cc2cc1 NCLDDWDALDODOQ-ADXZGYQBSA-N 0.000 description 1
- MUXHYALESSUDHQ-LJPZCQIFSA-N C[C@@H](CCC(O)=O)c1ccc(C(C(N(C)Cc(cc(cc2)N)c2C(N2CCCC2)=O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1C Chemical compound C[C@@H](CCC(O)=O)c1ccc(C(C(N(C)Cc(cc(cc2)N)c2C(N2CCCC2)=O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1C MUXHYALESSUDHQ-LJPZCQIFSA-N 0.000 description 1
- TVZITBMQSOFCLX-QUZMYUOTSA-N C[C@@H](CCC(OC)=O)c1c(C)cc(C(C(N(C)Cc(cc(cc2)[N+]([O-])=O)c2OC(F)(F)F)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 Chemical compound C[C@@H](CCC(OC)=O)c1c(C)cc(C(C(N(C)Cc(cc(cc2)[N+]([O-])=O)c2OC(F)(F)F)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 TVZITBMQSOFCLX-QUZMYUOTSA-N 0.000 description 1
- IKHHVROXPOKMKO-SZGIACGNSA-N C[C@@H](CN(C)C(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1OC(F)(F)F)=O)c1c(C)cc(C(C(OC)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 Chemical compound C[C@@H](CN(C)C(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1OC(F)(F)F)=O)c1c(C)cc(C(C(OC)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 IKHHVROXPOKMKO-SZGIACGNSA-N 0.000 description 1
- JYADKYQONZSBFX-TYKNXJODSA-N C[C@@H](CO)c1c(C)cc(C(C(N(CCOC)Cc2cc([N+]([O-])=O)ccc2)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 Chemical compound C[C@@H](CO)c1c(C)cc(C(C(N(CCOC)Cc2cc([N+]([O-])=O)ccc2)=O)Nc(cc2)cc3c2C=CNC3=O)cc1 JYADKYQONZSBFX-TYKNXJODSA-N 0.000 description 1
- YFGFJUKIMRTVTE-JZFIVBRMSA-N C[C@@H](CO)c1ccc(C(C(N[C@H](C)c2cccc([N+]([O-])=O)c2)=O)Nc(cc2)cc3c2C=CNC3=O)cc1C Chemical compound C[C@@H](CO)c1ccc(C(C(N[C@H](C)c2cccc([N+]([O-])=O)c2)=O)Nc(cc2)cc3c2C=CNC3=O)cc1C YFGFJUKIMRTVTE-JZFIVBRMSA-N 0.000 description 1
- FDKZPJABAGLRGP-GIFGLUKTSA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C(C2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1cnc(C)[n]1C)=O)c1ccc2cc1C Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C(C2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1cnc(C)[n]1C)=O)c1ccc2cc1C FDKZPJABAGLRGP-GIFGLUKTSA-N 0.000 description 1
- QTPMDHKCUDEDFP-LGIXDALBSA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C(CNc2ccc(/C=C\N)c(C=O)c2)=O)c1Oc1ccccc1)=O)c1ccccc1C Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C(CNc2ccc(/C=C\N)c(C=O)c2)=O)c1Oc1ccccc1)=O)c1ccccc1C QTPMDHKCUDEDFP-LGIXDALBSA-N 0.000 description 1
- ZESFFYYHSWVFNW-FLASPHMUSA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)c1N(CCCCC1)C1=O)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)c1N(CCCCC1)C1=O)=O)c1c(C)cc2cc1 ZESFFYYHSWVFNW-FLASPHMUSA-N 0.000 description 1
- HBNDMANBHYONDV-URAOTHONSA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1ncc[n]1C)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1ncc[n]1C)=O)c1c(C)cc2cc1 HBNDMANBHYONDV-URAOTHONSA-N 0.000 description 1
- SIRVHWVSXOPKJS-AFJIDDCJSA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1ncc[s]1)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1-c1ncc[s]1)=O)c1c(C)cc2cc1 SIRVHWVSXOPKJS-AFJIDDCJSA-N 0.000 description 1
- UDVFYCYOGGUYCT-XRHLQHRESA-N C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1Cl)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](COC(Nc(cc1)cc(CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)c1Cl)=O)c1c(C)cc2cc1 UDVFYCYOGGUYCT-XRHLQHRESA-N 0.000 description 1
- ORDPPRWKJOCXGG-FEAGIOCNSA-N C[C@@H](COC(Nc(cc1)cc(CNC)c1N(CCC1)C1=O)=O)c1ccc(C(C(O)=O)Nc(cc2)cc3c2C=CNC3=O)cc1C Chemical compound C[C@@H](COC(Nc(cc1)cc(CNC)c1N(CCC1)C1=O)=O)c1ccc(C(C(O)=O)Nc(cc2)cc3c2C=CNC3=O)cc1C ORDPPRWKJOCXGG-FEAGIOCNSA-N 0.000 description 1
- FBZYXYIUFYWUQU-IBGZPJMESA-N C[C@@H](COC(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1-[n]1cncc1)=O)c(cc1)c(C)cc1Br Chemical compound C[C@@H](COC(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1-[n]1cncc1)=O)c(cc1)c(C)cc1Br FBZYXYIUFYWUQU-IBGZPJMESA-N 0.000 description 1
- WCLRPUYPBUKCIF-LCUARMQBSA-N C[C@@H](COC(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1S(C1CC1)(=O)=O)=O)c1ccc(C(C(O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1 Chemical compound C[C@@H](COC(Nc(cc1CN(C)C(OC(C)(C)C)=O)ccc1S(C1CC1)(=O)=O)=O)c1ccc(C(C(O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1 WCLRPUYPBUKCIF-LCUARMQBSA-N 0.000 description 1
- DGHRQAGQQAYRCS-XRHLQHRESA-N C[C@@H](COC(Nc(cc1CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)ccc1OC(F)(F)F)=O)c1ccc2cc1C Chemical compound C[C@@H](COC(Nc(cc1CN(C)C([C@@H]2Nc(cc3)cc4c3C=CNC4=O)=O)ccc1OC(F)(F)F)=O)c1ccc2cc1C DGHRQAGQQAYRCS-XRHLQHRESA-N 0.000 description 1
- WHHQQUUOHNDNEM-HMILPKGGSA-N C[C@@H](COC(Nc(cc1CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)ccc1C#N)=O)c1c(C)cc2cc1 Chemical compound C[C@@H](COC(Nc(cc1CN(C)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)ccc1C#N)=O)c1c(C)cc2cc1 WHHQQUUOHNDNEM-HMILPKGGSA-N 0.000 description 1
- SXYTXTNREWOZCE-GTYOFVGBSA-N C[C@@H](COC(Nc1cc(CN(CCNC(OC(C)(C)C)=O)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)ccc1)=O)c1ccc2cc1C Chemical compound C[C@@H](COC(Nc1cc(CN(CCNC(OC(C)(C)C)=O)C([C@@H]2Nc3ccc(C=CNC4=O)c4c3)=O)ccc1)=O)c1ccc2cc1C SXYTXTNREWOZCE-GTYOFVGBSA-N 0.000 description 1
- ZPZIAIFYFFIERZ-JZFIVBRMSA-N C[C@@H](COC(Nc1cc([C@@H](C)N)ccc1)=O)c1c(C)cc(C(C(O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1 Chemical compound C[C@@H](COC(Nc1cc([C@@H](C)N)ccc1)=O)c1c(C)cc(C(C(O)=O)Nc2ccc(C=CNC3=O)c3c2)cc1 ZPZIAIFYFFIERZ-JZFIVBRMSA-N 0.000 description 1
- MFKPDYNNTWDJNM-UHFFFAOYSA-N C[N](C)(C)N(C=CC=N1)C1=O Chemical compound C[N](C)(C)N(C=CC=N1)C1=O MFKPDYNNTWDJNM-UHFFFAOYSA-N 0.000 description 1
- DGXULUVKSUEPAD-HHHXNRCGSA-N Cc(cc1)c(CN(C)C([C@@H](c2ccc(CCC3)cc2)Nc2ccc(CNC4=O)c4c2)=O)cc1NC3=O Chemical compound Cc(cc1)c(CN(C)C([C@@H](c2ccc(CCC3)cc2)Nc2ccc(CNC4=O)c4c2)=O)cc1NC3=O DGXULUVKSUEPAD-HHHXNRCGSA-N 0.000 description 1
- DZAGJSWXPQPNNP-UHFFFAOYSA-N Cc1cc(Br)cc(C)c1CNCC(OC)=O Chemical compound Cc1cc(Br)cc(C)c1CNCC(OC)=O DZAGJSWXPQPNNP-UHFFFAOYSA-N 0.000 description 1
- ABCVXHPLPQPISN-UHFFFAOYSA-N Cc1cc(C(C(N(C)Cc2cc([N+]([O-])=O)ccc2)=O)Nc(cc2)cc3c2C=CNC3=O)cc(C)c1CCO Chemical compound Cc1cc(C(C(N(C)Cc2cc([N+]([O-])=O)ccc2)=O)Nc(cc2)cc3c2C=CNC3=O)cc(C)c1CCO ABCVXHPLPQPISN-UHFFFAOYSA-N 0.000 description 1
- QCVPGMDYNOCNSK-UHFFFAOYSA-N Cc1cc(C(C(NCc(cc(cc2)N3)c2S(C)(=O)=O)=O)Nc(cc24)ccc2N=CNC4=O)cc(C)c1CN(CC(O)=O)CC3=O Chemical compound Cc1cc(C(C(NCc(cc(cc2)N3)c2S(C)(=O)=O)=O)Nc(cc24)ccc2N=CNC4=O)cc(C)c1CN(CC(O)=O)CC3=O QCVPGMDYNOCNSK-UHFFFAOYSA-N 0.000 description 1
- SGRPAMKKIGCIDX-UHFFFAOYSA-N Cc1cc(C(C(NCc(cc(cc2)NC(C3)=O)c2S(=O)=O)=O)Nc(cc2)cc4c2N=CNC4=O)cc(C)c1CN3OC(c1ccccc1)=O Chemical compound Cc1cc(C(C(NCc(cc(cc2)NC(C3)=O)c2S(=O)=O)=O)Nc(cc2)cc4c2N=CNC4=O)cc(C)c1CN3OC(c1ccccc1)=O SGRPAMKKIGCIDX-UHFFFAOYSA-N 0.000 description 1
- JJNCRKLSAULKQR-UHFFFAOYSA-N Cc1cc(C(C(O)=O)Nc(cc2)cc3c2C=CNC3=O)cc(C)c1CCO Chemical compound Cc1cc(C(C(O)=O)Nc(cc2)cc3c2C=CNC3=O)cc(C)c1CCO JJNCRKLSAULKQR-UHFFFAOYSA-N 0.000 description 1
- VSXCTCMFQVDJTB-UHFFFAOYSA-N NC(c(cc(cc1)[N+]([O-])=O)c1OC(F)(F)F)N Chemical compound NC(c(cc(cc1)[N+]([O-])=O)c1OC(F)(F)F)N VSXCTCMFQVDJTB-UHFFFAOYSA-N 0.000 description 1
- GSQUVIBWTKWASE-UHFFFAOYSA-N NN(CCc1ccccc11)C1=O Chemical compound NN(CCc1ccccc11)C1=O GSQUVIBWTKWASE-UHFFFAOYSA-N 0.000 description 1
- PAEMWNBWAKIGLQ-UHFFFAOYSA-N Nc(cc1)cc2c1C(F)=CNC2=O Chemical compound Nc(cc1)cc2c1C(F)=CNC2=O PAEMWNBWAKIGLQ-UHFFFAOYSA-N 0.000 description 1
- KKPITLYHSOXPTM-UHFFFAOYSA-N Nc1cc(C2NCCC2)ccc1 Chemical compound Nc1cc(C2NCCC2)ccc1 KKPITLYHSOXPTM-UHFFFAOYSA-N 0.000 description 1
- POQDPPCZQPFEDZ-DNVCBOLYSA-N O=C(Cc(ccc([BrH+])c1)c1Cl)N([C@](C1)(CO2)[C@H]1c1ccccc1)C2=O Chemical compound O=C(Cc(ccc([BrH+])c1)c1Cl)N([C@](C1)(CO2)[C@H]1c1ccccc1)C2=O POQDPPCZQPFEDZ-DNVCBOLYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N O=C1NC=CC=C1 Chemical compound O=C1NC=CC=C1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- YWPMKTWUFVOFPL-UHFFFAOYSA-N O=C1NCCc2ccccc12 Chemical compound O=C1NCCc2ccccc12 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 1
- XGYCWCIGCYGQFU-UHFFFAOYSA-N O=S1(NCCC1)=O Chemical compound O=S1(NCCC1)=O XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 description 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N O=S1(NCCCC1)=O Chemical compound O=S1(NCCCC1)=O DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 1
- ZDPJGAWPRHNQHI-QMMMGPOBSA-N OC[C@@H](c(cc1)ccc1Br)O Chemical compound OC[C@@H](c(cc1)ccc1Br)O ZDPJGAWPRHNQHI-QMMMGPOBSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N OCc1ccccc1 Chemical compound OCc1ccccc1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- MOBNCKURXDGQCB-UHFFFAOYSA-N [O-][N+](c(cc1)cc2c1N=CNC2=O)=O Chemical compound [O-][N+](c(cc1)cc2c1N=CNC2=O)=O MOBNCKURXDGQCB-UHFFFAOYSA-N 0.000 description 1
- PPXUVXCYQWPGGE-UHFFFAOYSA-N [O-][N+](c(cc1C=O)cc(F)c1O)=O Chemical compound [O-][N+](c(cc1C=O)cc(F)c1O)=O PPXUVXCYQWPGGE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87086406P | 2006-12-20 | 2006-12-20 | |
| US98446007P | 2007-11-01 | 2007-11-01 | |
| PCT/US2007/088032 WO2008079836A2 (en) | 2006-12-20 | 2007-12-19 | Macrocyclic factor viia inhibitors useful as anticoagulants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514681A true JP2010514681A (ja) | 2010-05-06 |
| JP2010514681A5 JP2010514681A5 (https=) | 2010-09-16 |
Family
ID=39430763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543158A Withdrawn JP2010514681A (ja) | 2006-12-20 | 2007-12-19 | 抗凝血剤として有用な大環状第ｖｉｉａ因子阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8420830B2 (https=) |
| EP (1) | EP2102176A2 (https=) |
| JP (1) | JP2010514681A (https=) |
| AR (1) | AR064471A1 (https=) |
| AU (1) | AU2007337025A1 (https=) |
| CA (1) | CA2673598A1 (https=) |
| CL (1) | CL2007003718A1 (https=) |
| MX (1) | MX2009006689A (https=) |
| NO (1) | NO20092279L (https=) |
| PE (1) | PE20081775A1 (https=) |
| TW (1) | TW200836735A (https=) |
| WO (1) | WO2008079836A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015506934A (ja) * | 2011-12-27 | 2015-03-05 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルアルキルカルバメート誘導体化合物およびこれを含む薬学組成物 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008079759A1 (en) | 2006-12-20 | 2008-07-03 | Bristol-Myers Squibb Company | Bicyclic lactam factor viia inhibitors useful as anticoagulants |
| CA2782384A1 (en) * | 2009-12-08 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| ES2674745T3 (es) * | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| CN102993065B (zh) * | 2011-09-13 | 2015-07-29 | 中国科学院上海药物研究所 | 含手性叔丁基亚磺酰基的α-芳基氨基酸酯类化合物、其制备方法及用途 |
| KR101937514B1 (ko) | 2011-10-14 | 2019-01-10 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물 |
| EP2858977A1 (en) | 2012-06-08 | 2015-04-15 | Bristol-Myers Squibb Company | Macrocyclic factor viia inhibitors |
| KR20150038369A (ko) * | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| MX361759B (es) * | 2012-08-03 | 2018-12-17 | Bristol Myers Squibb Co | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
| EP3008052A1 (en) * | 2013-06-13 | 2016-04-20 | Bristol-Myers Squibb Company | Macrocyclic factor viia inhibitors |
| CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
| NO2760821T3 (https=) | 2014-01-31 | 2018-03-10 | ||
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3072943B1 (en) | 2015-03-26 | 2018-05-02 | Idemitsu Kosan Co., Ltd. | Dibenzofuran/carbazole-substituted benzonitriles |
| ES2871111T3 (es) * | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US5023236A (en) | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
| US5843442A (en) | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
| US5866542A (en) | 1994-10-18 | 1999-02-02 | Corvas International, Inc. | Nematode-extracted anticoagulant protein |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| EP1192135A2 (en) | 1999-06-14 | 2002-04-03 | Eli Lilly And Company | Serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| WO2003011222A2 (en) * | 2001-07-27 | 2003-02-13 | Merck & Co., Inc. | Thrombin inhibitors |
| CA2461202C (en) | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2004072102A2 (en) | 2003-02-11 | 2004-08-26 | Bristol-Myers Squibb Company | Benzene acetamide compounds useful as serine protease inhibitors |
| EP1594505A4 (en) | 2003-02-11 | 2008-08-13 | Bristol Myers Squibb Co | PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS |
| PE20061117A1 (es) | 2005-01-10 | 2006-10-13 | Bristol Myers Squibb Co | DERIVADOS DE FENILGLICINAMIDA COMO INHIBIDORES DEL FACTOR VIIa |
| CA2600745A1 (en) * | 2005-03-03 | 2006-09-08 | The Burnham Institute For Medical Research | Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby |
| WO2007002313A2 (en) | 2005-06-24 | 2007-01-04 | Bristol-Myers Squibb Company | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants |
| AR058380A1 (es) | 2005-12-23 | 2008-01-30 | Bristol Myers Squibb Co | Inhibidores del factor viia macrociclicos utiles como anticoagulantes |
| US8044242B2 (en) | 2006-03-09 | 2011-10-25 | Bristol-Myers Squibb Company | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants |
| WO2008079759A1 (en) | 2006-12-20 | 2008-07-03 | Bristol-Myers Squibb Company | Bicyclic lactam factor viia inhibitors useful as anticoagulants |
-
2007
- 2007-12-14 PE PE2007001814A patent/PE20081775A1/es not_active Application Discontinuation
- 2007-12-19 CA CA002673598A patent/CA2673598A1/en not_active Abandoned
- 2007-12-19 CL CL200703718A patent/CL2007003718A1/es unknown
- 2007-12-19 WO PCT/US2007/088032 patent/WO2008079836A2/en not_active Ceased
- 2007-12-19 AU AU2007337025A patent/AU2007337025A1/en not_active Abandoned
- 2007-12-19 EP EP07869479A patent/EP2102176A2/en not_active Withdrawn
- 2007-12-19 JP JP2009543158A patent/JP2010514681A/ja not_active Withdrawn
- 2007-12-19 AR ARP070105750A patent/AR064471A1/es not_active Application Discontinuation
- 2007-12-19 TW TW096148731A patent/TW200836735A/zh unknown
- 2007-12-19 MX MX2009006689A patent/MX2009006689A/es not_active Application Discontinuation
- 2007-12-19 US US12/519,376 patent/US8420830B2/en active Active
-
2009
- 2009-06-12 NO NO20092279A patent/NO20092279L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015506934A (ja) * | 2011-12-27 | 2015-03-05 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルアルキルカルバメート誘導体化合物およびこれを含む薬学組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009006689A (es) | 2009-06-30 |
| WO2008079836A4 (en) | 2009-03-12 |
| US20100113488A1 (en) | 2010-05-06 |
| CA2673598A1 (en) | 2008-07-03 |
| NO20092279L (no) | 2009-08-31 |
| US8420830B2 (en) | 2013-04-16 |
| WO2008079836A2 (en) | 2008-07-03 |
| CL2007003718A1 (es) | 2008-07-11 |
| PE20081775A1 (es) | 2008-12-18 |
| AR064471A1 (es) | 2009-04-01 |
| TW200836735A (en) | 2008-09-16 |
| EP2102176A2 (en) | 2009-09-23 |
| WO2008079836A3 (en) | 2009-01-15 |
| AU2007337025A1 (en) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514681A (ja) | 抗凝血剤として有用な大環状第ｖｉｉａ因子阻害剤 | |
| JP6033319B2 (ja) | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 | |
| EP2978751B1 (en) | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors | |
| CN103702999B (zh) | 作为因子xia抑制剂的环状p1连接体 | |
| JP6082463B2 (ja) | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ | |
| JP6082462B2 (ja) | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ | |
| CN107074821B (zh) | 为fxia抑制剂的二酰胺大环化合物 | |
| US8039506B2 (en) | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | |
| EP3099688A1 (en) | Macrocyclic factor xia inhibitors condensed with heterocycles | |
| JP6816103B2 (ja) | 非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤 | |
| CN101611019A (zh) | 可用作抗凝血药的大环凝血因子Ⅶa抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100728 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100728 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120509 |